Phase II Study of Anti-GD2 3F8 Antibody and GM-CSF for High-Risk Neuroblastoma.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Oct 2018
At a glance
- Drugs Monoclonal antibody 3F8 (Primary) ; Sargramostim (Primary) ; Isotretinoin
- Indications Neuroblastoma
- Focus Therapeutic Use
- 03 Oct 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 03 Oct 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
- 31 Aug 2018 Biomarkers information updated